ArticleJournal of thoracic disease2026
Comparative prognostic analysis of primary thymic adenocarcinoma and squamous cell carcinoma: a 20-year retrospective real-world study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary thymic adenocarcinoma (PTAC) and primary thymic squamous cell carcinoma (PTSCC) are rare malignancies with unclear prognostic differences due to limited comparative studies. This study aimed to systematically analyze their clinicopathological features and survival outcomes in a Chinese cohort. Methods: In this retrospective cohort study, 70 patients (56 PTSCC, 14 PTAC) treated at Cancer Hospital Chinese Academy of Medical Sciences between [1999-2018] were analyzed. Clinicopathological data were collected, including Masaoka stage, treatment modalities, and resection status. Survival analysis used Kaplan-Meier curves and Cox regression. Propensity score matching (PSM) was applied for subgroup comparisons. Results: PTAC exhibited significantly worse overall survival (OS) than PTSCC [median survival time (MST): 1.29 Conclusions: PTAC is more aggressive than PTSCC, particularly in advanced stages. Pathological subtype stratification is critical for prognostication and treatment optimization. These findings underscore the need for subtype-specific management strategies in thymic carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.